Molecular Modelling Study of the PPARγ Receptor in Relation to the Mode of Action/Adverse Outcome Pathway Framework for Liver Steatosis

Ivanka Tsakovska 1,*, Merilin Al Sharif 1, Petko Alov 1, Antonia Diukendjieva 1, Elena Fioravanzo 2, Mark T. D. Cronin 3 and Ilza Pajeva 1,*

1 Institute of Biophysics and Biomedical Engineering—BAS, Acad. G. Bonchev Str., Bl.105, Sofia 1113, Bulgaria; E-Mails: merilin.al@biomed.bas.bg (M.A.S.); petko@biophys.bas.bg (P.A.); antonia.diuk@gmail.com (A.D.)
2 Soluzioni Informatiche srl, Via Ferrari 14, Vicenza 36100, Italy; E-Mail: elena.fioravanzo@s-in.it
3 School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK; E-Mail: M.T.Cronin@ljmu.ac.uk

* Authors to whom correspondence should be addressed;
E-Mails: ITsakovska@biomed.bas.bg (I.T.); pajeva@biomed.bas.bg (I.P.);
Tel.: +359-2-9793605 (I.T. & I.P.); Fax: +359-2-8723787 (I.T. & I.P.).

Received: 30 March 2014; in revised form: 18 April 2014 / Accepted: 21 April 2014 / Published: 5 May 2014

Abstract: The comprehensive understanding of the precise mode of action and/or adverse outcome pathway (MoA/AOP) of chemicals has become a key step toward the development of a new generation of predictive toxicology tools. One of the challenges of this process is to test the feasibility of the molecular modelling approaches to explore key molecular initiating events (MIE) within the integrated strategy of MoA/AOP characterisation. The description of MoAs leading to toxicity and liver damage has been the focus of much interest. Growing evidence underlines liver PPARγ ligand-dependent activation as a key MIE in the elicitation of liver steatosis. Synthetic PPARγ full agonists are of special concern, since they may trigger a number of adverse effects not observed with partial agonists. In this study, molecular modelling was performed based on the PPARγ complexes with full agonists extracted from the Protein Data Bank. The receptor binding pocket was analysed, and the specific ligand-receptor interactions were identified for the most active ligands. A pharmacophore model was derived, and the most important pharmacophore features were outlined and characterised in relation to their specific role for PPARγ activation. The results are useful for the characterisation of the chemical space of PPARγ.
full agonists and could facilitate the development of preliminary filtering rules for the effective virtual ligand screening of compounds with PPARγ full agonistic activity.

**Keywords:** PPARγ; liver steatosis; mode of action; molecular modelling; pharmacophore

### 1. Introduction

Modern toxicology concepts aim at building alternative models (*in vitro* and *in silico*) to predict the adverse effects of chemicals. This requires comprehensive understanding of biological pathways starting at the molecular level and their relationship to adverse effects at the organ and higher levels of organism organization [1]. These concepts are based on the adverse outcome pathway (AOP) methodology and lie at the heart of initiatives, such as SEURAT-1 (http://www.seurat-1.eu) and TOX21 (http://www.epa.gov/ncct/Tox21/). The AOP methodology supports the use of a mode of action (MoA) framework involving the description and characterisation of the key cytological and biochemical events that are both measurable and necessary for the observed effect [2].

Within the MoA/AOP framework, the description and characterisation of the toxicological MoAs leading to liver toxicity are of specific interest, since the liver is a major organ affected by toxicity. *In silico* approaches are suitable tools to study the starting events of these MoAs—the molecular initiating events (MIE). Recently, molecular modelling approaches have been proposed for the study of the MIEs involved in liver steatosis [3,4]. They include hepatic PPARγ activation, which has been noted as being one of the probable MIEs leading to non-alcoholic fatty liver disease, including liver steatosis [5,6].

The peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the steroid-thyroid hormone superfamily of ligand-activated transcription factors. It has been well studied in the last decade, because of its important role in glucose and lipid homeostasis. The mechanisms of PPARγ genomic activity (transactivation and transrepression) have been comprehensively studied. The nuclear receptor forms a heterodimer with another nuclear receptor, retinoid X receptor alpha (RXRα), and binds to specific DNA sequences in the promoter regions of target genes. PPARγ binds and responds to diverse endogenic lipid metabolites, including eicosanoids and fatty acids [7]. The activation of PPARγ is induced by specific conformational changes upon ligand binding; these changes release corepressors and allow for the recruitment of coactivators.

PPARγ has two isoforms, PPARγ1 and PPARγ2, the latter possessing an additional thirty amino acids in the N-terminal part. It has an overall domain structure typical for nuclear hormone receptors comprised of: an N-terminal AF-1 (transactivation function 1) domain that participates in the interaction with cofactors and is responsible for ligand-independent transactivation; a DBD (DNA binding domain) that is highly conserved among nuclear receptors; a highly flexible hinge region, necessary for nuclear localisation and cofactor docking; and a C-terminal LBD/AF-2 (ligand binding domain/activation function 2) that participates in ligand-binding, ligand-dependent transactivation, coactivator recruitment and corepressor release (Figure 1).
Figure 1. Schematic structure of the functional domains of the PPARγ isoforms (transactivation function domain 1 (AF1) DNA-binding domain (DBD), ligand-binding domain (LBD) and transactivation function domain 2 (AF2)).

Synthetic PPARγ ligands are primarily categorised based on their transactivation activity into full and partial agonists [8]. The full agonists, despite their clinical benefit (e.g., as antidiabetic agents [9]), have been associated with adverse side effects, including hepatotoxicity [10,11]. Thus, the prediction of the full agonistic effect of synthetic PPARγ ligands is of specific interest in the field of toxicology.

Significant efforts have been made in understanding the ligand-dependent activation of PPARγ. Studies show that binding to the helix12 (H12) of the receptor is required for full agonist activity [12]. Full agonists that interact with PPARγ generally involve a polar terminal group and a hydrophobic moiety. The polar group forms hydrogen bonds (HBs) with the receptor residues Ser289, His323, His449 and Tyr473. These HBs are responsible for the conformational change of H12 and, subsequently, the activation of PPARγ [13].

In this study, we performed a comprehensive analysis of the PPARγ binding pocket and the interactions of full agonists-PPARγ based on the 3D PPARγ complexes deposited in the Protein Data Bank (http://www.rcsb.org) [14]. A pharmacophore model was developed based on the most active ligands, and it was evaluated on a dataset of full agonists extracted from PDB. The pharmacophore features were evaluated according to their role in PPARγ interactions and the transactivation activity of the full agonists.

2. Results and Discussion

2.1. Analysis of the PPARγ LBD and Ligand-Receptor Interactions

The PPARγ LBD and the ligand interactions were analysed based on the agonist complexes extracted from PDB and subsequently 3D-protonated at appropriate physiological conditions to assign the correct ionisation state and positions of the missing H-atoms. The complexes differed in the type of the bound ligands (Figure 2a) and the receptors (Figure 2b). Some of the complexes had two ligands simultaneously occupying the LBD [15–17].
Figure 2. Distribution of the structures according to the type of: (a) the bound ligands; (b) the receptors.

The protein structures of the complexes were next superposed on the X-ray structure of the PPARγ-rosiglitazone complex (PDB ligand ID BRL; complex ID 1FM6, [18]). This complex was selected as an appropriate template in the subsequent modelling steps, because of the following reasons: (i) the complex represents a physiologically relevant heterodimer of the human RXRα and PPARγ LBDs, respectively, bound with 9-cis retinoic acid and rosiglitazone and co-activator peptides; (ii) rosiglitazone is one of the most active agonists among the PPARγ ligands (Table S1), thus providing a relevant structure for the purposes of pharmacophore modelling; (iii) the LBD of the complex consists of 272 residues (from Pro206 to Tyr477), thus fully covering the main structural elements of the domain; (iv) compared to other complexes of PPARγ with rosiglitazone (4EMA, 3DZY, 2PRG, 3CS8, [19–22]) available in PDB, that selected has the lowest resolution of 2.1 Å (the complex with PDB ID 1ZGY [23] has been resolved at 1.80 Å; however, it is not crystallised with RXRα and, thus, does not reflect physiological conditions). Due to this, the 1FM6 complex appears to be the most appropriate template, due to its physiologically relevant form and low resolution.

The complexes were superposed on the C-alpha atoms of both X and D-chains of the 1FM6 complex, and the root-mean-square deviation (RMSD) values were recorded. In general, the superposition on the D-chain produced better RMSDs; thus, the superposition on the D-chain of the 1FM6 complex was selected to produce the overlay of all bioactive conformations of the PPARγ full agonists.

Considering the fact that the X-ray structure may represent a “tensed” conformation of the ligand due to the crystal packing forces, we compared the structure of rosiglitazone as extracted from the 1FM6 complex and the one that has been relaxed using the MMFF94s force field. The X-ray and relaxed structures were very close (RMSD 0.388 Å upon superposition on all heavy atoms and 0.377 Å on the heteroatoms only). Figure 3 illustrates the structures superimposed on the heteroatoms. The distances between the oxygen atoms were 0.34 and 0.45 Å, and the nitrogen atoms in the thiazolidine rings were fully overlaid. As shown below, these atoms are involved in the specific interactions of rosiglitazone with PPARγ. The small differences in the space location of the most important atoms imply that the X-ray ligand conformation may not be strongly influenced by the crystallisation. To support this suggestion further, we superposed the heavy atoms of the rosiglitazone
structure extracted from all available complexes. The RMSD values in the interval 0.18–0.58 Å (template: rosiglitazone structure from 1FM6 complex, D chain) were recorded, indicating that the variations in rosiglitazone conformations between the complexes were small (Table S1). This is in agreement with previous studies on the optimisation of X-ray complexes of another nuclear receptor (human estrogen receptor α) at different levels of protein flexibility and, so, points to the fact that the ligand X-ray structures represent a stable bioactive conformation [24].

Figure 3. Superposed structures of rosiglitazone: the X-ray structure (PDB ID 1FM6) is shown in the atom type colour and the carbon atoms of the structure optimised by the MMFF94s force field are coloured in green. The structures are superposed on the heteroatoms, and the distances between the oxygen atoms in the thiazolidine ring are in Å.

Figure 4a illustrates the PPARγ LBD and 58 full and partial agonists superposed on the template complex 1FM6 with rosiglitazone. Figure 4b shows the template structure with the binding pocket outlined by its surface (within 4.5 Å of the ligand atoms). The binding pocket is large (~1300 Å³, [21]) and can accommodate more than one ligand in more than one binding mode. It has a complex form, as seen from the three main directions (Arm I, II and III) occupied by the bound ligands. The entrance to the pocket does not coincide with either of the arms: it is in the direction of the anchor point of the arms and is located between H3 and the strands. In the binding pocket, the polar parts of the ligands are directed to H12 in Arm I; the helix proved to play a key role for the binding of coactivators.

Analysis of the binding pocket of the nine most active agonists described the amino acids forming the receptor-binding pocket (Figure 5). Nineteen out of 48 residues are involved in the binding sites of all agonists, and Ser289, His323, His449 and Tyr473 (shown in red) have been detected to form hydrogen bonds in the analysis of the ligand-receptor interactions of the most active agonists. At the same time, sixteen residues have been detected in one or two complexes, indicating some flexibility of the binding site depending on the bound ligand.

Figure 6 illustrates the ligand-protein interactions of rosiglitazone in the PPARγ complex 1FM6 and GW409544 (PDB ligand ID 544) in complex 1K74 [25]. Ser289, His323, His449 and Tyr473 were the key receptor residues involved in HB interactions with the ligands.
**Figure 4.** (a) PPARγ and 58 agonists superposed on the template complex PDB ID 1FM6 with rosiglitazone (in space-filled rendering and C-atoms coloured in magenta); the other ligands are rendered in lines and coloured according to atom type; (b) surface map of the binding site (in constant grey colouring) of all agonists and rosiglitazone (in magenta); the coloured residues outline the corresponding arms within the binding site: Arm I, green; Arm II, cyan; Arm III, yellow; the entrance to the pocket (outlined with a black dotted line) is located between the arms; the protein backbone is rendered in ribbon and coloured according to the secondary structure: helix, red; strand, yellow; turn, blue; loop, white; H1–H12 assign the numbers of the helices in the PPARγ LBD structure.

**Figure 5.** The number of occurrences of the amino acids involved in the binding pockets of the nine most active agonists (according to the EC₅₀ values in Table S1); in red are the amino acids that were identified to form hydrogen bonds (HBs) with the most active agonists.
Figure 6. Ligand-interaction diagrams of (a) rosiglitazone and (b) GW409544 within the binding pocket of PPARγ.

Inspection of the binding pocket of all agonists confirms the observations that partial agonists occupy different regions, suggesting different modes of binding from H12 stabilisation for activation of PPARγ by the partial agonists (Figure 7) [12].

Figure 7. Binding poses of three full agonists (BRL (rosiglitazone), 544 (GW409544) 570 (farglitazar); in magenta) and three partial agonists (MRL24, SR145, SR147; in green) within the PPARγ binding pocket (template complex 1FM6).

2.2. Pharmacophore Development

Prior to pharmacophore development, the full agonists’ complexes were superposed on the template structure of 1FM6. The RMSD values of the superposed structures are reported in Table S1, and Figure 8 illustrates the histogram of the RMSD values. The RMSD values over the superposed structures vary from 0.44 to 1.58 Å. The largest number of structures falls into the interval 0.8–1.2 Å. A closer
investigation of the deviations of the protein chains showed that they relate mostly to the loop between H2’ and H3 (Figure 4a), while the helices that form the binding site appear well superposed. The flexibility of the H2’-H3 loop suggests that it might play a role in the accommodation of ligands of different form and size and, hence, preserving the positions of the helices in the PPARγ binding pocket. Thus, the PPARγ binding site remains relatively stable upon binding of different ligands, and the superposed ligands can represent a reliable alignment for pharmacophore generation.

**Figure 8.** Histogram of the RMSD values (X-axis) of superposed PPARγ-full agonist complexes (Y-axis).

The pharmacophore model was built based on the three most active agonists (Figure 9). It outlines seven important pharmacophore features that were observed in the most active agonists: four polar atoms and functional groups capable of performing HB and ionic interactions (F1, F2, F4 and F6) and three hydrophobic and aromatic structural elements (F3, F5 and F7). The hydrophobic/aromatic features stabilize the positions of the hydrophilic ones; the terminal F5 and F7 features are directed inside the pocket Arms I and II and contribute additionally to the stabilisation of the ligand pose into the pocket, ensuring the optimal position of the F1 and F2 features. Similar functions can be assigned to the F4 and F6 features interacting with the protein residues, either directly or through water molecules. The pharmacophore features and their possible role in the interaction within the binding pocket are summarised in Table 1.

**Figure 9.** Pharmacophore model of PPARγ full agonists (rosiglitazone, carbon atoms in magenta; compound 544, carbon atoms in green; compound 570, carbon atoms in grey).
**Table 1.** Description of the pharmacophore features in the pharmacophore model of the full PPARγ agonists. Don, donor; Acc, acceptor; Hyd, hydrophobic; Aro, aromatic.

| Pharmacophore feature | Location | Interactions |
|-----------------------|----------|--------------|
| F1: Don/Acc Arm I     |           | Participates in HB interactions (donor and acceptor) with residues His449 (H11) and Tyr473 (H12); responsible for the direct interaction with H12 and stabilises its active position |
| F2: Acc Arm I         |           | Participates in HB interactions (acceptor) with Ser289 (H3), His323(H5), Tyr 327 (H5); responsible for the stabilization of H12 in an active position |
| F3: Hyd/Aro Arm I     |           | Fits to the hydrophobic environment; stabilises the positions of F1 and F2 features |
| F4: Don/Acc Arm II    |           | Can participate in HB interactions directly or mediated by water molecules with Ser342 (H5), Cys285 (H3) and Arg 288 (H3); stabilises the pose of the ligand into the pocket |
| F5: Hyd/Aro Arm II    |           | Fits to the hydrophobic environment; stabilises the pose of the ligand into the pocket |
| F6: Don/Acc Arm I     |           | Can participate in HB interactions mediated by water; stabilises the pose of the ligand into the pocket |
| F7: Hyd/Aro Arm I     |           | Fits to the hydrophobic environment; stabilises the pose of the ligand into the pocket |

It should be noted that the seven-feature pharmacophore model is rather restrictive, since it is based on the most active agonists. Thus, the pharmacophore model was evaluated further among 21 full agonists from PDB, selected based on reliable data about their full agonistic activity and experimental transactivation EC50 values available in the source papers. The search was performed by superposition of the agonist structures on the pharmacophore model and estimation of the correspondence between pharmacophore points and their respective substructures. The results are reported in Table 2. Most of the compounds comprise 4–5 pharmacophore features. All of them contain either F1 or F2 or both simultaneously. The other pharmacophore features stabilise the position of the ligand in the pocket: in Arm II (by F4 and/or F5) or in Arm I (by F6 or/and F7). Features F1 or/and F2 and F3 could be outlined as mandatory for full agonism; at least one of the other features (F4–F7) is necessary for the full agonism. The most active agonists contain the highest number of pharmacophore features, whilst some of them are missing from the less active agonists.

In order to investigate in details how H12 is influenced by the ligand interactions, an analysis of the HB interactions between the ligands and the protein, as well as the contacts between amino acids of H12 and its vicinity and other amino acids in the PPARγ LBD was performed for the 21 complexes with full agonists. The apo-form (1PRG, [21]) was also included in the analysis for comparison. The results are summarised in Table S2. A number of ligands interact directly with H12 through HBs (e.g., S44, 570, BRL, ZAA), thus fitting to the F1 feature. For others (e.g., M7R, M7S, S44, J53) no interactions are identified with H12; instead, they interact with H3 and/or H5 fitting in this way with the F2 feature. At the same time, inspection of the protein contacts between the amino acids of H12 and its vicinity to other amino acids in the LBD reveals unique HBs that take place in complexes only and are not observed in the apo-forms. These new contacts connect H12 to H3, H4, and H5, thus
stabilising its active position (e.g., Ile472 (H12) with Lys319 (H4), Lys474 (after H12) with Lys319 (H4), Tyr477 (after H12) with Glu324 (H5), Hys466 (between H10/11 and H12) with Gln286 (H3); Table S2, highlighted lines). In the most active agonists, the HB contacts between H12 and H4 are recorded; in those that miss F1, HB contacts of H12 to H3 prevail. Obviously, such interactions facilitated by the ligand binding contribute to the stabilisation of the active position of H12, necessary for coactivator recruitment.

Table 2. Evaluation of the pharmacophore model on a dataset of full agonists: F1–F7, pharmacophore features; +/-, the presence or absence of the particular pharmacophore feature in the particular chemical structure; EC50, transactivation activity; the complexes are ordered according to their EC50 values (the lowest value considered when the interval data are reported).

| Complex PDB ID, [Ref.] | Ligand PDB ID | Pharmacophore features | EC50 (nM) |
|------------------------|---------------|-------------------------|-----------|
| 1K74 [25]              | 544           | + + + + + +            | 0.2–2.7   |
| 1FM9 [18]              | 570           | + + + + + +            | 0.339–6   |
| 1FM6 [18]              | BRL           | + + + + + –            | 2.4–2880  |
| 3AN4 [26]              | M7R           | – + + + + –            | 3.6       |
| 3BC5 [27]              | ZAA           | + – + + + –            | 4         |
| 3IA6 [28]              | UNT           | + + + + + –            | 13        |
| 1I7I [29]              | AZ2           | + + + – – – +          | 13–3528   |
| 3G9E [30]              | RO7           | + + + + + –            | 21        |
| 3AN3 [26]              | M7S           | – + + + + –            | 22        |
| 2ZNO [31]              | S44           | – + + + + –            | 41–70     |
| 3GBK [32]              | 2PQ           | + + + + + –            | 50        |
| 3VJU [33]              | J53           | – + + + – –            | 58        |
| 2F4B [34]              | EHA           | + – + – + –            | 70        |
| 2Q8S [35]              | L92           | + + + + + –            | 140       |
| 1KNU [36]              | YPA           | + + + + + –            | 170       |
| 3FEJ [37]              | CTM           | + + + – + –            | 210       |
| 2HWR [38]              | DRD           | + + + – + –            | 210       |
| 2ATH [39]              | 3EA           | + + + – + –            | 230       |
| 2XKW [40]              | P1B           | + + + + + –            | 280       |
| 1NYX [41]              | DRF           | + + + – + –            | 570–600   |
| 2GTK [42]              | 208           | + + + + + –            | 760       |

3. Experimental Section

MOE software was used to prepare structures (3D-protonated), to superpose and calculate the RMSD values of the extracted complexes and to develop the pharmacophore model of the PPAR full agonists [43].
3.1. PPARγ Structural and Activity Data

One hundred twenty available complexes of the human PPARγ receptor were extracted from PDB (last access: 15 February 2014). The experimental PPARγ activity data for the ligands identified in the complexes were collected from PDB and ChEMBL databases [44]. The data include binding affinity and transcriptional activity values ($K_i$, $K_d$, $IC_{50}$, $EC_{50}$) as obtained in competition binding assays, the scintillation proximity assay and transcriptional activation assays (Table S1).

3.2. Preparation of the Protein Structures (Protonate 3D)

In order to prepare the initial structures of the receptor, namely to assign the correct ionisation states and to position hydrogen atoms in the X-ray PPARγ protein structures, the MOE tool “Protonate 3D” was used. The addition of hydrogen atoms by this application is related to the determination of: the rotamers of –SH, –OH, –CH$_3$ and –NH$_3$ groups in Cys, Ser, Tyr, Thr, Met, Lys; the ionisation states of acids and bases in Arg, Asp, Glu, Lys, His; the tautomers of imidazoles (His) and carboxylic acids (Asp, Glu); the protonation state of metal ligand atoms in Cys, His, Asp, Glu, etc.; the ionisation state of metals; and the element identities in His and the terminal amides (Asn, Gln). In the application, the generalised Born/volume integral electrostatics model was used for the optimization of the titration free energies of all titratable groups. The physiologically relevant conditions were set (temperature: 310 K; pH = 7.4; ion concentration: 0.152 mol/L).

3.3. Analysis of the Ligand-Receptor Interactions

The MOE tool “Ligand Interactions” was applied to perform the analysis of the ligand-receptor interactions in the PPARγ complexes. The application identifies a number of interactions (hydrogen bonds, salt bridges, hydrophobic interactions, cation-$\pi$, sulphur-lone pair, halogen bonds and solvent exposure) between the ligand and the receptor-interacting entities as HB residues, close, but non-bonded residues (approaching the ligand, but not having any strong interactions, i.e., HBs), solvent molecules and ions. The HB interactions between pairs of heavy atoms from the ligand and the receptor are identified according to probability criteria derived from a large training set. The HB scores are expressed as percentages, and the HB directionality is noted. In the study, the default were applied.

3.4. Superposition of the Complexes

The LBDs of all extracted PDB complexes of PPARγ agonists were superposed on a template structure by the C-alpha atoms, and the RMSD values were recorded using the “Protein superpose” tool in MOE.

3.5. Pharmacophore Development

The pharmacophore was developed using the “Pharmacophore Query Editor” tool in MOE. The application refers to the generation of a pharmacophore hypothesis for the binding interactions in a particular active site. In MOE, the computerised representation of a hypothesised pharmacophore is called a pharmacophore query. An MOE pharmacophore query is a set of query features that are typically created from ligand annotation points.
Annotation points can be broadly divided into three categories, atom, projected and centroid, the latter including bioisosteres: (i) atom annotations are located directly on an atom of a molecule and typically indicate a function related to protein-ligand binding (these include the H-bond donor (Don), the H-bond acceptor (Acc), cation (Cat), anion (Ani), metal ligator (ML) and hydrophobic atom (HydA); (ii) projected annotations are located along implicit lone pair or implicit hydrogen directions and are used to annotate the location of possible partners for hydrogen bond or metal ligation or possible R-group atom locations. These include: projected donor (Don2), projected acceptor (Acc2), projected metal ligator (ML2) and ring projection (PiN); and (iii) centroid annotations are located at the geometric centre of a subset of the atoms of a molecule: aromatic (Aro), pi-ring (PiR) and hydrophobic (Hyd).

The annotation points on a ligand are the potential locations of the features that will constitute the pharmacophore query and are automatically detected in MOE. Annotation points relevant to the pharmacophore are converted into query features with the addition of an extra parameter: a non-zero radius that encodes the permissible variation in the pharmacophore query’s geometry.

4. Conclusions

In summary, a comprehensive analysis was performed on the available PDB complexes of PPARγ with full agonists. A pharmacophore model was derived demonstrating the importance of hydrogen bonding and hydrophobic features for full agonistic activity. The pharmacophore features were evaluated according to their role in the interaction with PPARγ H12 and the transactivation activity of the full agonists. It is envisaged that the pharmacophore model developed will be used for the in silico screening of agonists of hepatic PPARγ that can function as steatogenic inducer molecules.

Acknowledgments

The funding from the European Community’s 7th Framework Program (FP7/2007–2013) COSMOS Project under grant agreement No. 266835 and from Cosmetics Europe is gratefully acknowledged.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Cronin, M.T.D.; Richarz, A.N. Mode of action working group: Use of mode of action related to repeated dose systemic toxicity—A framework for capturing Information. In Towards the Replacement of in Vivo Repeated Dose Systemic Toxicity Testing; Gocht, T., Schwarz, M., Eds.; Imprimerie: Mouzet, France, 2012; Volume 2, pp. 284–289.

2. Organisation for Economic Co-operation and Development (OECD). Guidance Document on Developing and Assessing Adverse Outcome Pathways; Series on Testing and Assessment No. 184; OECD: Paris, France, 2013.

3. Fioravanzo, E.; Bassan, A.; Cronin, M.T.D.; Kovarich, S.; Manelfi, C.; Richarz, A.N.; Tsakovska, I.; Worth, A.P. Molecular modelling of LXR binding to evaluate the potential for liver steatosis. Toxicol. Lett. 2013, 221, S83.
4. Al Sharif, M.; Alov P, Cronin, M.; Fioravanzo, E.; Tsakovska, I.; Vitcheva, V.; Worth, A.; Yang, C.; Pajeva, I. Toward better understanding of liver steatosis MoA: Molecular modelling study of PPAR gamma receptor. *Toxicol. Lett.* **2013**, *221*, S85.

5. Al Sharif, M.; Alov, P.; Vitcheva, V.; Pajeva, I.; Tsakovska, I. Modes-of-action related to repeated dose toxicity: Tissue-specific biological roles of PPARγ ligand-dependent dysregulation in nonalcoholic fatty liver disease. *PPAR Res.* **2014**, *2014*, 432647:1–432647:13.

6. Landesmann, B.; Goumenou, M.; Munn, S.; Whelan, M. Description of Prototype Modes-Of-Action Related to Repeated dose Toxicity. Reference Report by the Joint Research Centre of the European Commission, Institute for Health and Consumer Protection, 2012, 40 Pages, EUR 25631 EN. Available online: http://publications.jrc.ec.europa.eu (accessed on 27 March 2014).

7. Costa, V.; Gallo, M.A.; Letizia, F.; Aprile, M.; Casamassimi, A.; Ciccodicola, A. PPARγ: Gene expression regulation and next-generation sequencing for unsolved issues. *PPAR Res.* **2010**, *2010*, 409168:1–409168:17.

8. Kouskoumvekaki, I.; Petersen, R.K.; Fratev, F.; Taboureau, O.; Nielsen, T.E.; Oprea, T.I.; Sonne, S.B.; Flindt, E.N.; Jónsdóttir, S.Ó.; Kristiansen, K. Discovery of a Novel Selective PPARγ Ligand with Partial Agonist Binding Properties by Integrated *in Silico*/*in Vitro* Work Flow. *J. Chem. Inf. Model.* **2013**, *53*, 923–937.

9. Day, C. Thiazolidinediones: A new class of antidiabetic drugs. *Diabet. Med.* **1999**, *16*, 179–192.

10. Moya, M.; Gómez-Lechón, M.J.; Castell, J.V.; Jover, R. Enhanced steatosis by nuclear receptor ligands: A study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. *Chem. Biol. Interact.* **2010**, *184*, 376–387.

11. Pan, H.J.; Lin, Y.; Chen, Y.E.; Vance, D.E.; Leiter, E.H. Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: Relation to dysregulated phosphatidylcholine metabolism. *Vascul. Pharmacol.* **2006**, *45*, 65–71.

12. Bruning, J.B.; Chalmers, M.J.; Prasad, S.; Busby, S.A.; Kamenecka, T.M.; He, Y.; Nettles, K.W.; Griffin, P.R. Partial agonists activate PPARgamma using a helix 12 independent mechanism. *Structure* **2007**, *15*, 1258–1271.

13. Guasch, L.; Sala, E.; Castell-Auvi, A.; Cedó, L.; Liedl, K.R.; Wolber, G.; Muehlbacher, M.; Mulero, M.; Pinent, M.; Ardévol, A.; *et al.* Identification of PPARgamma partial agonists of natural origin (I): Development of a virtual screening procedure and *in vitro* validation. *PLoS One* **2012**, *7*, e50816.

14. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. *Nucleic Acids Res.* **2000**, *28*, 235–242.

15. Waku, T.; Shiraki, T.; Oyama, T.; Maebara, K.; Nakamori, R.; Morikawa, K. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites. *EMBO J.* **2010**, *29*, 3395–3407.

16. Itoh, T.; Fairall, L.; Amin, K.; Inaba, Y.; Szanto, A.; Balint, B.L.; Nagy, L.; Yamamoto, K.; Schwabe, J.W. Structural basis for the activation of PPARγ by oxidized fatty acids. *Nat. Struct. Mol. Biol.* **2008**, *15*, 924–931.

17. Li, Y.; Zhang, J.; Schopfer, F.J.; Martynowski, D. Garcia-Barrio, M.T.; Kovach, A.; Suino-Powell, K.; Baker, P.R.; Freeman, B.A.; Chen, Y.E.; *et al.* Molecular recognition of nitrated fatty acids by PPARγ. *Nat. Struct. Mol. Biol.* **2008**, *15*, 865–867.
18. Gampe, R.T., Jr.; Montana, V.G.; Lambert, M.H.; Miller, A.B.; Bledsoe, R.K.; Milburn, M.V.; Kliewer, S.A.; Willson, T.M.; Xu, H.E. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. *Mol Cell.* 2000, 5, 545–555.

19. Liberato, M.V.; Nascimento, A.S.; Ayers, S.D.; Lin, J.Z.; Cvoro, A.; Silveira, R.L.; Martínez, L.; Souza, P.C.; Saidemberg, D.; Deng, T.; *et al.* Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR)γ activators and pan-PPAR partial agonists. *PLoS One* 2012, 7, e36297.

20. Chandra, V.; Huang, P.; Hamuro, Y.; Raghuram, S.; Wang, Y.; Burris, T.P.; Rastinejad, F. Structure of the intact PPAR-γ-RXR-nuclear receptor complex on DNA. *Nature* 2008, 456, 350–356.

21. Nolte, R.T.; Wisely, G.B.; Westin, S.; Cobb, J.E.; Lambert, M.H.; Kurokawa, R.; Rosenfeld, M.G.; Willson, T.M.; Glass, C.K.; Milburn, M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. *Nature* 1998, 395, 137–143.

22. Li, Y.; Kovach, A.; Suino-Powell, K.; Martynowski, D.; Xu, H.E. Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1α. *J. Biol. Chem.* 2008, 283, 19132–19139.

23. Li, Y.; Choi, M.; Suino, K.; Kovach, A.; Daugherty, J.; Kliewer, S.A.; Xu, H.E. Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. *Proc. Natl. Acad. Sci. USA* 2005, 102, 9505–9510.

24. Pencheva, T.; Jereva, D.; Miteva, M.; Pajeva, I. Post-docking optimization and analysis of protein-ligand interactions of estrogen receptor alpha using ammos software. *Curr. Comput. Aided Drug Des.* 2012, 9, 83–94.

25. Xu, H.E.; Lambert, M.H.; Montana, V.G.; Plunket, K.D.; Moore, L.B.; Collins, J.L.; Oplinger, J.A.; Kliewer, S.A.; Gampe, R.T., Jr.; McKee, D.D.; *et al.* Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. *Proc. Natl. Acad. Sci. USA* 2001, 98, 13919–13924.

26. Ohashi, M.; Oyama, T.; Nakagome, I.; Satoh, M.; Nishio, Y.; Nobusada, H.; Hirono, S.; Morikawa, K.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: Discovery of reversed stereochemistry-activity relationship. *J. Med. Chem.* 2011, 54, 331–341.

27. Zhang, H.; Ryono, D.E.; Devasthale, P.; Wang, W.; O’Malley, K.; Farrelly, D.; Gu, L.; Harrity, T.; Cap, M.; Chu, C.; *et al.* Design, synthesis and structure-activity relationships ofazole acids as novel, potent dual PPAR alpha/gamma agonists. *Bioorg. Med. Chem. Lett.* 2009, 19, 1451–1456.

28. Casimiro-Garcia, A.; Bigge, C.F.; Davis, J.A.; Padalino, T.; Pulaski, J.; Ohren, J.F.; McConnell, P.; Kane, C.D.; Royer, L.J.; Stevens, K.A.; *et al.* Synthesis and evaluation of novel α-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists. *Bioorg. Med Chem.* 2009, 17, 7113–7125.

29. Cronet, P.; Petersen, J.F.; Folmer, R.; Blomberg, N.; Sjöblom, K.; Karlsson, U.; Lindstedt, E.L.; Bamberg, K. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. *Structure* 2001, 9, 699–706.
30. Bénardeau, A.; Benz, J.; Binggeli, A.; Blum, D.; Boehringer, M.; Grether, U.; Hilpert, H.; Kuhn, B.; Märki, H.P.; Meyer, M.; et al. Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes. *Bioorg. Med. Chem. Lett.* 2009, 19, 2468–2473.

31. Oyama, T.; Toyota, K.; Waku, T.; Hirakawa, Y.; Nagasawa, N.; Kasuga, J.I.; Hashimoto, Y.; Miyachi, H.; Morikawa, K. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. *Acta. Crystallogr. D Biol. Crystallogr.* 2009, 65, 786–795.

32. Lin, C.H.; Peng, Y.H.; Coumar, M.S.; Chittimalla, S.K.; Liao, C.C.; Lyn, P.C.; Huang, C.C.; Lien, T.W.; Lin, W.H.; Hsu, J.T.; et al. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists. *J. Med. Chem.* 2009, 52, 2618–2622.

33. Kuwabara, N.; Oyama, T.; Tomioka, D.; Ohashi, M.; Yanagisawa, J.; Shimizu, T.; Miyachi, H. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: Phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype. *J. Med. Chem.* 2012, 55, 893–902.

34. Mahindroo, N.; Wang, C.C.; Liao, C.C.; Huang, C.F.; Lu, I.L.; Lien, T.W.; Peng, Y.H.; Huang, W.J.; Lin, Y.T.; Hsu, M.C.; et al. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: Design, synthesis, structural biology, and molecular docking studies. *J. Med. Chem.* 2006, 49, 1212–1216.

35. Casimiro-Garcia, A.; Bigge, C.F.; Davis, J.A.; Padalino, T.; Pulaski, J.; Ohren, J.F.; McConnell, P.; Kane, C.D.; Royer, L.J.; Stevens, K.A.; et al. Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARα/γ dual agonists, and X-ray crystallographic studies. *Bioorg. Med. Chem.* 2008, 16, 4883–4907.

36. Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P.S.; Mogensen, J.P.; Wassermann, K.; Brand, C.L.; Sturis, J.; Wöldike, H.F.; Fleckner, J.; et al. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: Dual PPARα/γ agonists with hypolipidemic and antidiabetic activity. *J. Med. Chem.* 2002, 45, 789–804.

37. Grether, U.; Bénardeau, A.; Benz, J.; Binggeli, A.; Blum, D.; Hilpert, H.; Kuhn, B.; Märki, H.P.; Meyer, M.; Mohr, P.; et al. Design and biological evaluation of novel, balanced dual PPARα/γ agonists. *ChemMedChem* 2009, 4, 951–956.

38. Mahindroo, N.; Peng, Y.H.; Lin, C.H.; Tan, U.K.; Prakash, E.; Lien, T.W.; Lu, I.L.; Lee, H.J.; Hsu, J.T.; Chen, X.; et al. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. *J. Med. Chem.* 2006, 49, 6421–6424.

39. Mahindroo, N.; Huang, C.F.; Peng, Y.H.; Wang, C.C.; Liao, C.C.; Lien, T.W.; Chittimalla, S.K.; Huang, W.J.; Chai, C.H.; Prakash, E.; et al. Novel indole-based peroxisome proliferator-activated receptor agonists: Design, SAR, structural biology, and biological activities. *J. Med. Chem.* 2005, 48, 8194–8208.

40. Mueller, J.J.; Schupp, M.; Unger, T.; Kintscher, U.; Heinemann, U. Binding Diversity of Pioglitazone by Peroxisome Proliferator-Activated Receptor-Gamma. Unpublished work, 2011.

41. Ebdrup, S.; Pettersson, I.; Rasmussen, H.B.; Deussen, H.J.; Frost Jensen, A.; Mortensen, S.B.; Fleckner, J.; Pridal, L.; Nygaard, L.; Sauerberg, P. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. *J. Med. Chem.* 2003, 46, 1306–1317.
42. Kuhn, B.; Hilpert, H.; Benz, J.; Binggeli, A.; Grether, U.; Humm, R.; Märki, H.P.; Meyer, M.; Mohr, P. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4016–4020.

43. *MOE (Molecular Operating Environment) Version 2013.08*; Chemical Computing Group Inc.: Montreal, QC, Canada, 2013.

44. Gaulton, A.; Bellis, L.J.; Bento, A.P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; *et al.* ChEMBL: A large-scale bioactivity database for drug discovery. *Nucleic Acids Res.* **2012**, *40*, D1100–D1107.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).